AIM
CYCN icon

Alambic Investment Management’s Cyclerion Therapeutics CYCN Stock Holding History

Alambic Investment Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-515
Closed -$63K – 14
2020
Q3 		$63K Sell
515
-538
-51% -$61.5K 0.69% 51
2020
Q2 		$124K Sell
1,053
-10
-0.9% -$836 0.31% 120
2020
Q1 		$56K Sell
1,063
-1,150
-52% -$82K 0.14% 160
2019
Q4 		$120K Buy
+2,213
New +$207K 0.1% 237

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alambic Investment Management's CYCN Position: Q4 2020 in Review

Alambic Investment Management sold out of Cyclerion Therapeutics (CYCN) in Q4 2020, closing a stake of 515 shares — an estimated $63K sold.

Alambic Investment Management first reported a position in CYCN in Q4 2019 and held it in 4 quarters. The position peaked at $124K in Q2 2020. 73 funds tracked by Wall St. Rank hold CYCN as of Q4 2020.

  • Alambic Investment Management reported no remaining Cyclerion Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Alambic Investment Management sold 515 Cyclerion Therapeutics shares in Q4 2020, an estimated $63K.
  • Alambic Investment Management first reported a position in Cyclerion Therapeutics in Q4 2019 and held it in 4 quarters.
  • Alambic Investment Management's Cyclerion Therapeutics position peaked at $124K in Q2 2020.
  • 73 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2020.

Based on Alambic Investment Management's 13F filing for Q4 2020.